Despite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at the time of writing – the need to strike new trade deals has led to secret trade discussions be
Globally, balancing rising healthcare costs with the drive for innovation is a political hot potato – is a greater focus on patient-reported data the centre of value-based gravity we’ve bee
NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend a treatment at around £50,000 per Quality Adjusted Life Year (QALY) – is a young policy i
We talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future of genomic medicines and how healthcare systems may need to adapt to
The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies.